AtheroGenics gains on AGI-1067 data

AtheroGenics (NASDAQ:AGIX) gained $0.29 (53%) to $0.84 on Thursday after AGI-1067 met the primary endpoint of significantly reducing HbA1c levels in the Phase III ANDES trial to treat Type II diabetes...